

TRACKING YOUR SESSION ATTENDANCE

Use this worksheet to help you keep track of your session attendance. This worksheet is for your reference only and should **not** be returned to NCCN. Completion of this worksheet is **not required** to claim continuing education credit. **NOTE:** CE/MOC credit should be claimed for the Congress as a whole, not session by session. You may claim credit for the Congress **only one time**.



Attended	Time (Listed in EDT)	Session	Credit (AMA/ACPE/ANCC/AAPA)
FRIDAY, SEPTEMBER 18, 2026			
☐	1:00 – 1:35 PM	Transforming the Management of Acute Lymphoblastic Leukemia	0.5
☐	1:35 – 2:05 PM	Oral Targeted Therapies in Relapsed/Refractory Acute Myeloid Leukemia	0.5
☐	2:05 – 2:35 PM	Chronic Myeloid Leukemia: De-Escalation of TKI Therapy	0.5
☐	2:35 – 3:05 PM	Managing Toxicities of Outpatient Oral Therapies for Chronic Myeloid Leukemia	0.5
☐	3:25 – 3:55 PM	The Role of Clonal Hematopoiesis in Hematologic Malignancies	0.5
☐	3:55 – 5:30 PM	Evolving Treatment Strategies in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma	1.5
SATURDAY, SEPTEMBER 19, 2026			
☐	8:00 – 9:05 AM	Outpatient Administration of Bispecific Antibodies and CAR T-Cell Therapies	1.0
☐	9:05 – 10:20 AM	Managing Toxicities of Bispecific Antibodies and CAR T-Cell Therapies in the Outpatient Setting	1.25
☐	10:40 – 11:10 AM	Working Toward Unified Classification of Hematolymphoid Malignancies	0.5
☐	11:10 – 11:40 AM	Current and Emerging Treatment Options for Peripheral T-Cell Lymphomas	0.5
☐	12:40 – 1:25 PM	Chronic Lymphocytic Leukemia: Navigating First-Line and MRD-Guided Treatment Options	0.75
☐	1:25 – 1:55 PM	Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma	0.5
☐	2:10 – 2:40 PM	Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	0.5
☐	2:40 – 3:10 PM	Update on the Diagnosis and Management of Marginal Zone Lymphomas	0.5
☐	3:10 – 4:00 PM	Collaborative Strategies for Optimizing Small-Volume Drug Delivery	0.75
ON-DEMAND, ONLINE-ONLY SESSIONS			
☐	ON DEMAND	Individualizing Treatment for Patients with Waldenström Macroglobulinemia	0.5
☐	ON DEMAND	Erdheim-Chester Disease: The Role of Molecular Testing in Treatment Planning	0.75
☐	ON DEMAND	The Evolving Treatment Landscape in Myeloproliferative Neoplasms	0.5
☐	ON DEMAND	Advances in Systemic Mastocytosis	0.75
☐	ON DEMAND	Treating Adult Patients with Burkitt Lymphoma	0.5
☐	ON DEMAND	Psychosocial Support for Adolescent and Young Adult Patients with Hematologic Malignancies	0.75
Total			14.0